Satraplatin, an Oral Platinum, Administered on a Five-day Every-Five-Week Schedule: a Pharmacokinetic and Food Effect StudyRICART, Alejandro D; SARANTOPOULOS, John; CALVO, Emiliano et al.Clinical cancer research (Print). 2009, Vol 15, Num 11, pp 3866-3871, issn 1078-0432, 6 p.Article

Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group StudySHIBATA, Stephen I; CHUNG, Vincent; O'NEIL, Bert H et al.Clinical cancer research (Print). 2013, Vol 19, Num 13, pp 3631-3639, issn 1078-0432, 9 p.Article

A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid TumorsRODON, Jordi; TAWBI, Hussein A; LIN YANG et al.Clinical cancer research (Print). 2014, Vol 20, Num 7, pp 1900-1909, issn 1078-0432, 10 p.Article

Predicting success in regulatory approval from Phase I resultsMALIK, Laeeq; MEJIA, Alex; PARSONS, Helen et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 5, pp 1099-1103, issn 0344-5704, 5 p.Article

Phase I Dose-Escalation Study of VB-111, an Antiangiogenic Virotherapy, in Patients with Advanced Solid TumorsBRENNER, Andrew J; COHEN, Yael C; BREITBART, Eyal et al.Clinical cancer research (Print). 2013, Vol 19, Num 14, pp 3996-4007, issn 1078-0432, 12 p.Article

Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumorsMUHAMMAD WASIF SAIF; SARANTOPOULOS, John; PATNAIK, Amita et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 6, pp 1565-1573, issn 0344-5704, 9 p.Article

Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanomaMAHALINGAM, Devalingam; MALIK, Laeeq; WRIGHT, John et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 1, pp 77-84, issn 0344-5704, 8 p.Article

Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid TumorsROSEN, Lee S; PUZANOV, Igor; MITA, Alain C et al.Clinical cancer research (Print). 2012, Vol 18, Num 12, pp 3414-3427, issn 1078-0432, 14 p.Article

A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumorsRICART, Alejandro D; ASHTON, Edward A; ZAMBITO, Angela et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 4, pp 959-970, issn 0344-5704, 12 p.Article

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid TumorsMITA, Alain C; TAKIMOTO, Chris H; ZHONG, Z. Don et al.Clinical cancer research (Print). 2010, Vol 16, Num 11, pp 3044-3056, issn 1078-0432, 13 p.Article

Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxelSARANTOPOULOS, John; MITA, Alain C; WADE, James L et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 6, pp 1113-1124, issn 0344-5704, 12 p.Article

Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumorsMAHALINGAM, Devalingam; NEMUNAITIS, John J; CHARLES, John et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 6, pp 1241-1250, issn 0344-5704, 10 p.Article

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432LORUSSO, Patricia M; VENKATAKRISHNAN, Karthik; TAKIMOTO, Chris H et al.Clinical cancer research (Print). 2012, Vol 18, Num 10, pp 2954-2963, issn 1078-0432, 10 p.Article

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyLEAL, Ticiana B; REMICK, Scot C; MIER, James et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 6, pp 1439-1447, issn 0344-5704, 9 p.Article

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1TOLCHER, Anthony W; SARANTOPOULOS, John; KAISER, Brianne et al.Journal of clinical oncology. 2009, Vol 27, Num 34, pp 5800-5807, issn 0732-183X, 8 p.Article

Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumorsCURTIS, Kelly K; SARANTOPOULOS, John; NORTHFELT, Donald W et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 5, pp 931-941, issn 0344-5704, 11 p.Article

Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumorsLOCKHART, A. Craig; SUNDARAM, Shankar; DEDIEU, Jean-Francois et al.Investigational new drugs. 2014, Vol 32, Num 6, pp 1236-1245, issn 0167-6997, 10 p.Article

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumorsNEMUNAITIS, John; MITA, Alain; STEPHENSON, Joe et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 1, pp 35-41, issn 0344-5704, 7 p.Article

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neckSEIWERT, Tanguy; SARANTOPOULOS, John; KALLENDER, Howard et al.Investigational new drugs. 2013, Vol 31, Num 2, pp 417-424, issn 0167-6997, 8 p.Article

Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group StudyRAMALINGAM, Suresh S; KUMMAR, Shivaani; IVY, S. Percy et al.Journal of clinical oncology. 2010, Vol 28, Num 29, pp 4507-4512, issn 0732-183X, 6 p.Article

Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumorsLIN, Chia-Chi; CALVO, Emiliano; YEH, I-Tien et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 6, pp 1065-1071, issn 0344-5704, 7 p.Article

Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignanciesMITA, Monica; MITA, Alain; SARANTOPOULOS, John et al.Cancer chemotherapy and pharmacology. 2009, Vol 64, Num 2, pp 287-295, issn 0344-5704, 9 p.Article

A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced MalignanciesPAPADOPOULOS, Kyriakos P; GOEL, Sanjay; SARANTOPOULOS, John et al.Clinical cancer research (Print). 2008, Vol 14, Num 21, pp 7110-7115, issn 1078-0432, 6 p.Article